Page last updated: 2024-10-28

hydralazine and Cardiomegaly

hydralazine has been researched along with Cardiomegaly in 90 studies

Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.

Cardiomegaly: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.

Research Excerpts

ExcerptRelevanceReference
"The ability of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor simvastatin to reverse established cardiovascular and renal alterations and oxidative stress was assessed in angiotensin II (AngII) hypertension."7.74Simvastatin reverses target organ damage and oxidative stress in Angiotensin II hypertension: comparison with apocynin, tempol, and hydralazine. ( Delbosc, S; Jover, B; Mimran, A; Rugale, C, 2007)
"The objectives were two-fold: (1) determine whether the use of hydralazine as antihypertensive therapy during obesity development exacerbated obesity-related cardioacceleration and hormonal abnormalities; (2) determine whether the absence of hypertension in obesity attenuated obesity-related abnormalities in hemodynamics, cardiac hypertrophy, and hormonal profile."7.72Hydralazine as antihypertensive therapy in obesity-related hypertension. ( Carroll, JF; Cohen, JS; King, JW, 2004)
" We tested the hypothesis that endothelin (ET)(A/B) receptor blockade with bosentan (100 mg/kg by gavage after age 4 weeks) ameliorates cardiac and renal damage by decreasing inflammation in rats harboring both human renin and angiotensinogen genes (dTGR)."7.70Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. ( Breu, V; Dechend, R; Ganten, D; Genersch, E; Haller, H; Löffler, BM; Luft, FC; Mervaala, EM; Muller, DN; Park, JK; Schmidt, F; Schneider, W, 2000)
"The role of angiotensin II (ANG II) in the development of isoproterenol (Iso)-induced cardiac hypertrophy was examined in rats."7.69Angiotensin II maintains, but does not mediate, isoproterenol-induced cardiac hypertrophy in rats. ( Abassi, ZA; Cuda, G; Golomb, E; Keiser, HR; Panchal, VR; Stylianou, M; Trachewsky, D, 1994)
"The present study was designed to investigate the effect of nicardipine administration upon systolic blood pressure (SBP) and cardiac hypertrophy in spontaneously hypertensive rats (SHR)."7.68Effect of nicardipine treatment upon cardiac hypertrophy in spontaneously hypertensive rats: a morphometric and ultrastructural study. ( Amenta, F; Bronzetti, E; Ciriaco, E; Felici, L; Ferrante, F, 1992)
"Evidence of cardiac hypertrophy was slow to resolve despite good control of blood pressure."6.64Double-blind comparison of minoxidil and hydrallazine in severe hypertension. ( Bennett, CM; Connor, G; Wilburn, RL, 1976)
"However, cardiac hypertrophy, evaluated by echocardiography, heart weight, cross-sectional area of cardiomyocytes, and gene expression, was inhibited by only Olm treatment, but not by Hyd."5.43Olmesartan Inhibits Cardiac Hypertrophy in Mice Overexpressing Renin Independently of Blood Pressure: Its Beneficial Effects on ACE2/Ang(1-7)/Mas Axis and NADPH Oxidase Expression. ( Ichikawa, H; Kimura, Y; Kinjo, T; Narita, I; Nishizaki, K; Okumura, K; Osanai, T; Tanaka, M; Tanno, T; Tomita, H, 2016)
"Hydralazine was administered with Ang II infusion (n=10)."5.34Synergetic antioxidant and vasodilatory action of carbon monoxide in angiotensin II - induced cardiac hypertrophy. ( Ishikawa, K; Kamiyama, Y; Kimura, S; Kobayashi, A; Maruyama, Y; Matsumoto, H, 2007)
" Since left ventricular hypertrophy may be an important determinant of outcome in hypertension, the long-term effects of arterial vasodilation with hydralazine on left ventricular mass and function were compared with those of an alternative third-line drug, the alpha1 blocker prazosin, in patients still hypertensive despite combined diuretic and beta blocker therapy."5.06Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans. ( Farkas, RM; Leenen, FH; Marquez-Julio, A; Reeves, RA; Smith, DL, 1987)
" Another set of rats were treated with hydralazine (25 mg/kg per day orally) to determine the pressure-independent effects of HDAC inhibition on hypertension."3.76HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. ( Cardinale, JP; Elks, CM; Francis, J; Guggilam, A; Mariappan, N; Pariaut, R; Sriramula, S, 2010)
" Sensitivity of VSCR control of efferent renal sympathetic nerve activity (RSNA) in SHR is restored when cardiac hypertrophy and hypertension are reduced by enalapril treatment."3.74Role of cardiac hypertrophy in reducing the sensitivity of cardiopulmonary reflex control of renal sympathetic nerve activity in spontaneously hypertensive rats. ( Abreu, GR; Bissoli, NS; de Andrade, TU; de Melo Cabral, A; Moysés, MR, 2008)
"The ability of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor simvastatin to reverse established cardiovascular and renal alterations and oxidative stress was assessed in angiotensin II (AngII) hypertension."3.74Simvastatin reverses target organ damage and oxidative stress in Angiotensin II hypertension: comparison with apocynin, tempol, and hydralazine. ( Delbosc, S; Jover, B; Mimran, A; Rugale, C, 2007)
"Azelnidipine suppressed cardiac hypertrophy, fibrosis, NADPH oxidase and superoxide in spSHRs more potently than amlodipine, and was associated with lower heart rates than amlodipine."3.73Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis. ( Ito, T; Kataoka, K; Kim-Mitsuyama, S; Lai, ZF; Ogawa, H; Tanaka, T; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2006)
"The objectives were two-fold: (1) determine whether the use of hydralazine as antihypertensive therapy during obesity development exacerbated obesity-related cardioacceleration and hormonal abnormalities; (2) determine whether the absence of hypertension in obesity attenuated obesity-related abnormalities in hemodynamics, cardiac hypertrophy, and hormonal profile."3.72Hydralazine as antihypertensive therapy in obesity-related hypertension. ( Carroll, JF; Cohen, JS; King, JW, 2004)
" Stroke-prone spontaneously hypertensive Izumo strain rats were divided into four groups, treated with vehicle, the angiotensin-converting enzyme inhibitor (ACEI) delapril (40 mg/kg per d), the angiotensin receptor antagonist (AT1R-Ant) candesartan cilexetil (1 mg/kg per d), or the vasodilator hydralazine (25 mg/kg per d) from weaning to puberty (3 to 10 wk of age), and then monitored without treatment for 6 mo."3.71Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. ( Hayashi, M; Nakaya, H; Saruta, T; Sasamura, H, 2001)
"To evaluate the relation of tissue-localized angiotensin II (Ang II) concentration with cardiac hypertrophy and glomerulosclerosis in Tsukuba hypertensive mice (THM) carrying both human renin and angiotensinogen genes."3.70Tissue-localized angiotensin II enhances cardiac and renal disorders in Tsukuba hypertensive mice. ( Fukamizu, A; Ishikawa, K; Kai, T; Kurooka, A; Murakami, K; Shimada, S; Sugimura, K; Takenaka, T, 1998)
"Although evidence has been accumulated to support a role of endothelin-1 (ET-1) in cardiac hypertrophy, details of the pathophysiological significance of ET-1 in cardiac hypertrophy remain to be elucidated."3.70Hydralazine decreases blood pressure and endothelin-1 mRNA expression in tissues but not cardiac weight in SHR-SP/Izm rats. ( Adachi, C; Naruse, K; Naruse, M; Seki, T; Takagi, S; Takano, K; Tanabe, A; Yoshimoto, T, 2000)
" We tested the hypothesis that endothelin (ET)(A/B) receptor blockade with bosentan (100 mg/kg by gavage after age 4 weeks) ameliorates cardiac and renal damage by decreasing inflammation in rats harboring both human renin and angiotensinogen genes (dTGR)."3.70Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. ( Breu, V; Dechend, R; Ganten, D; Genersch, E; Haller, H; Löffler, BM; Luft, FC; Mervaala, EM; Muller, DN; Park, JK; Schmidt, F; Schneider, W, 2000)
" The role of the renin-angiotensin system (RAS) in cardiac hypertrophy and nephropathy was examined in Tsukuba hypertensive mice (THM) carrying both human renin and angiotensinogen genes."3.70Renin-angiotensin system stimulates cardiac and renal disorders in Tsukuba hypertensive mice. ( Ishikawa, K; Kai, T; Kurooka, A; Shimada, S; Sugimura, K, 1999)
"The role of angiotensin II (ANG II) in the development of isoproterenol (Iso)-induced cardiac hypertrophy was examined in rats."3.69Angiotensin II maintains, but does not mediate, isoproterenol-induced cardiac hypertrophy in rats. ( Abassi, ZA; Cuda, G; Golomb, E; Keiser, HR; Panchal, VR; Stylianou, M; Trachewsky, D, 1994)
"A blunted reduction in total left ventricular load, due to increased pulsatile load in SHR treated with hydralazine, provided a hemodynamic basis for the differential regression of hypertrophy in this model of genetic hypertension."3.69Equipotent antihypertensive agents variously affect pulsatile hemodynamics and regression of cardiac hypertrophy in spontaneously hypertensive rats. ( Finn, PV; Mitchell, GF; Pfeffer, JM; Pfeffer, MA, 1996)
"The blood pressure was decreased after chronic treatment with enalapril, MK-954, and hydralazine in deoxycorticosterone acetate (DOCA)-salt-induced malignant hypertension of spontaneously hypertensive rats (SHR); however, ventricular weight and plasma brain natriuretic peptide (BNP) concentration were decreased after enalapril and MK-954 but not after hydralazine."3.69Cardiac hypertrophy and brain natriuretic peptide in experimental hypertension. ( Fukui, T; Horio, T; Kohno, M; Kurihara, N; Takeda, T; Yasunari, K; Yokokawa, K; Yoshiyama, M, 1994)
"The present study was designed to investigate the effect of nicardipine administration upon systolic blood pressure (SBP) and cardiac hypertrophy in spontaneously hypertensive rats (SHR)."3.68Effect of nicardipine treatment upon cardiac hypertrophy in spontaneously hypertensive rats: a morphometric and ultrastructural study. ( Amenta, F; Bronzetti, E; Ciriaco, E; Felici, L; Ferrante, F, 1992)
"To assess a possible involvement of cardiac volume overload in the development of cardiac hypertrophy during chronic arterial vasodilator treatment, changes in indexes of cardiac volume load in relation to changes in cardiac anatomy were evaluated during treatment of normotensive rats with 120 mg/l hydralazine or 120 mg/l minoxidil, with drinking water."3.67Arterial vasodilators, cardiac volume load, and cardiac hypertrophy in normotensive rats. ( Leenen, FH; Tsoporis, J; Yuan, BX, 1989)
"To determine if a remodeling of the collagen matrix would occur in the absence of hypertrophy and cell necrosis and if such a remodeling could alter active and passive stiffness of the intact myocardium, five rats with genetic hypertension (SHR) were treated (SHRT) with hydralazine for 32 weeks, beginning at four weeks of age, and compared to six age- and sex-matched SHR and seven Wistar-Kyoto genetic control rats (WKY)."3.67Myocardial collagen and mechanics after preventing hypertrophy in hypertensive rats. ( Janicki, JS; Narayan, S; Pick, R; Shroff, SG; Weber, KT, 1989)
"To investigate the relationship between cardiac hypertrophy associated with hypertension, and the alterations in myocardial lipid metabolism, nicardipine (160 mg/kg/day), hydralazine (40 mg/kg/day), and enalapril (30 mg/kg/day) were administered to spontaneously hypertensive rats from 20 to 24 weeks of age."3.67Fatty acid binding protein of cardiac muscle in spontaneously hypertensive rats: effect of hypertrophy and its regression. ( Fujii, S; Kawaguchi, H; Okamoto, H; Saito, H; Togashi, H; Yasuda, H, 1988)
" In order to study the relative roles of hypertension and cardiac hypertrophy in the depression of SHR function, 20-week old SHRs and normotensive rats were treated for 10 weeks with either hydralazine (100 mg X litre-1) or alpha-methyldopa (8 g X litre-1)."3.66Effect of antihypertensive therapy on calcium transport by cardiac sarcoplasmic reticulum of SHRs. ( Limas, CJ; Spier, SS, 1980)
"Ventricular arrhythmia was a significant independent predictor in V-HeFT II but not in V-HeFT I."2.67Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. ( Cohn, JN; Fletcher, R; Johnson, GR; Loeb, H; Rector, T; Shabetai, R; Smith, R; Tristani, F, 1993)
"Evidence of cardiac hypertrophy was slow to resolve despite good control of blood pressure."2.64Double-blind comparison of minoxidil and hydrallazine in severe hypertension. ( Bennett, CM; Connor, G; Wilburn, RL, 1976)
"However, it is generally accepted that cardiac hypertrophy is one of the most critical risk factors of heart disease."2.40Role of the renin-angiotensin system in cardiac hypertrophy. ( Komuro, I; Yamazaki, T; Yazaki, Y, 1999)
"However, cardiac hypertrophy, evaluated by echocardiography, heart weight, cross-sectional area of cardiomyocytes, and gene expression, was inhibited by only Olm treatment, but not by Hyd."1.43Olmesartan Inhibits Cardiac Hypertrophy in Mice Overexpressing Renin Independently of Blood Pressure: Its Beneficial Effects on ACE2/Ang(1-7)/Mas Axis and NADPH Oxidase Expression. ( Ichikawa, H; Kimura, Y; Kinjo, T; Narita, I; Nishizaki, K; Okumura, K; Osanai, T; Tanaka, M; Tanno, T; Tomita, H, 2016)
"Hydralazine did not affect cardiac hypertrophy in wild-type mice and mice lacking either AT(1) or AT(2) receptors alone."1.36Vasodilator therapy with hydralazine induces angiotensin AT receptor-mediated cardiomyocyte growth in mice lacking guanylyl cyclase-A. ( Harada, M; Horiuchi, M; Kishimoto, I; Kuwahara, K; Li, Y; Murray, M; Nakao, K; Rong, X; Saito, Y, 2010)
"Olmesartan was associated with a significantly reduced myocyte hypertrophy index (4."1.36Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin II type 1 receptor blocker olmesartan. ( Hatipoglu, FO; Hirohata, S; Iwamoto, M; Kusachi, S; Miyoshi, T; Ninomiya, Y; Ogawa, H; Ohtsuki, T; Shinohata, R; Yamamoto, K, 2010)
"Hydralazine was administered with Ang II infusion (n=10)."1.34Synergetic antioxidant and vasodilatory action of carbon monoxide in angiotensin II - induced cardiac hypertrophy. ( Ishikawa, K; Kamiyama, Y; Kimura, S; Kobayashi, A; Maruyama, Y; Matsumoto, H, 2007)
"Our data suggest that 1) cardiac hypertrophy in SHRs is partly due to NF-kappaB activation, 2) inhibition of NF-kappaB activity by PDTC parallels regression of hypertrophy, and 3) regression of hypertrophy is partly due to inhibition of NF-kappaB activity, independent of hypertension."1.33Inhibition of NF-kappaB induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats. ( Gupta, S; Sen, S; Young, D, 2005)
"Cardiac hypertrophy was reduced by all three treatments, but to a lesser extent by hydralazine (treatment study), and this regression of cardiac hypertrophy persisted only with both types of RAS inhibition (withdrawal study)."1.31Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats. ( Paull, JR; Widdop, RE, 2001)
"Regression of cardiac hypertrophy was accompanied by a 50% to 300% increase in DNA fragmentation and a >20% reduction in DNA synthesis, resulting in a >20% reduction in cardiac DNA content after 4 weeks."1.30Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats. Temporal regulation and spatial heterogeneity. ( Dam, TV; deBlois, D; Hamet, P; Moreau, P; Tea, BS, 1999)
"Cardiac hypertrophy was shown to be related to age and gender with the copy number of mouse renin transgenes having an additive effect."1.30Different effects of antihypertensive agents on cardiac and vascular hypertrophy in the transgenic rat line TGR(mRen2)27. ( Brosnan, MJ; Clark, JS; Devlin, AM; Dominiczak, AF; Mullins, JJ, 1999)
"Cardiac hypertrophy was assessed by the left ventricle plus septum weight to body weight ratio and vascular hypertrophy by flow-cytometry analysis of vascular smooth muscle cell polyploidy."1.30Telemetry for cardiovascular monitoring in a pharmacological study: new approaches to data analysis. ( Anderson, NH; Devlin, AM; Dominiczak, AF; Graham, D; Hamilton, CA; Morton, JJ; Reid, JL; Schork, NJ, 1999)
"Cardiac hypertrophy was also observed after chronic inhibition of nitric oxide synthesis."1.29Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. ( Egashira, K; Kadokami, T; Numaguchi, K; Shimokawa, H; Sueishi, K; Takemoto, M; Takeshita, A, 1995)
"Treatment with hydralazine decreased blood pressure in a similar way as trandolapril but did not affect either LV weight or LV Ang II."1.28Role of cardiac angiotensin II in isoproterenol-induced left ventricular hypertrophy. ( Higaki, J; Higashimori, K; Mikami, H; Nagano, M; Nagano, N; Nakamura, F; Ogihara, T, 1992)
"Captopril was less effective in improving maximal coronary blood flow but was as effective as cilazapril in reducing cardiac hypertrophy."1.28Effects of two angiotensin converting enzyme inhibitors and hydralazine on coronary circulation in hypertensive rats. ( Clozel, JP; Hess, P; Sprecher, U; Véniant, M, 1991)
"Hydralazine treatment normalized blood pressure in SHR but did not cause regression of cardiac hypertrophy (heart weight to body weight ratio of SHR + hydralazine 4."1.28Vascular remodeling and improvement of coronary reserve after hydralazine treatment in spontaneously hypertensive rats. ( Anderson, PG; Bishop, SP; Digerness, SB, 1989)
"Hydralazine tended to lower LV MCVR per 100 g in both strains despite its tendency to increase ventricular mass."1.28Role of lowering arterial pressure on maximal coronary flow with and without regression of cardiac hypertrophy. ( Canby, CA; Tomanek, RJ, 1989)
"Treatment with hydralazine did not affect left ventricular weight and caused a small increase in the weight of the right ventricle."1.27Effects of arterial vasodilators on cardiac hypertrophy and sympathetic activity in rats. ( Leenen, FH; Tsoporis, J, 1988)
"Even though cardiac hypertrophy is viewed as a beneficial compensatory process that normalizes wall stress, the increased muscle mass carries with it the need of increased blood supply."1.27Effects of vasodilators on the coronary circulation in congestive heart failure. ( Burkart, F; Kiowski, W, 1988)
"Hydralazine treatment prevented hypertension in DOCA + HYD but did not prevent development of cardiac hypertrophy (heart weight/body weight of DOCA + HYD 3."1.27Coronary vascular function and morphology in hydralazine treated DOCA salt rats. ( Anderson, PG; Bishop, SP; Digerness, SB, 1988)
"Prehydralazine baseline data were therefore compared with values 35 minutes after hydralazine."1.26Hemodynamic effects of hydralazine in infants with a large ventricular septal defect. ( Beekman, RH; Rocchini, AP; Rosenthal, A, 1982)

Research

Studies (90)

TimeframeStudies, this research(%)All Research%
pre-199035 (38.89)18.7374
1990's25 (27.78)18.2507
2000's23 (25.56)29.6817
2010's7 (7.78)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Thandapilly, SJ1
Louis, XL1
Behbahani, J1
Movahed, A1
Yu, L1
Fandrich, R1
Zhang, S1
Kardami, E1
Anderson, HD1
Netticadan, T1
Katayama, IA2
Pereira, RC1
Dopona, EP1
Shimizu, MH1
Furukawa, LN2
Oliveira, IB2
Heimann, JC2
Tanno, T1
Tomita, H1
Narita, I1
Kinjo, T1
Nishizaki, K1
Ichikawa, H1
Kimura, Y1
Tanaka, M1
Osanai, T1
Okumura, K1
de Andrade, TU1
Abreu, GR1
Moysés, MR1
de Melo Cabral, A1
Bissoli, NS1
Siedlecki, AM1
Jin, X1
Muslin, AJ1
Kawamura, M1
Itoh, H1
Yura, S1
Mogami, H1
Fujii, T1
Kanayama, N1
Konishi, I1
Li, Y1
Saito, Y1
Kuwahara, K1
Rong, X1
Kishimoto, I1
Harada, M1
Horiuchi, M1
Murray, M1
Nakao, K1
Cardinale, JP1
Sriramula, S1
Pariaut, R1
Guggilam, A1
Mariappan, N1
Elks, CM1
Francis, J1
Ferreira, DN1
Rosa, KT1
Coelho, MS1
Casarini, DE1
Iwamoto, M1
Hirohata, S1
Ogawa, H2
Ohtsuki, T1
Shinohata, R1
Miyoshi, T1
Hatipoglu, FO1
Kusachi, S1
Yamamoto, K1
Ninomiya, Y1
Sanada, S2
Node, K2
Asanuma, H3
Ogita, H2
Takashima, S3
Minamino, T4
Asakura, M2
Liao, Y1
Ogai, A2
Kim, J2
Hori, M3
Kitakaze, M4
Carroll, JF1
King, JW1
Cohen, JS1
Gupta, S1
Young, D1
Sen, S4
Okazaki, H1
Tsukamoto, O1
Okada, K1
Myoishi, M1
Wakeno, M1
Mochizuki, N1
Liang, Q1
Elson, AC1
Gerdes, AM1
Yamamoto, E1
Lai, ZF1
Yamashita, T1
Tanaka, T1
Kataoka, K1
Tokutomi, Y1
Ito, T1
Kim-Mitsuyama, S1
Baumann, M1
Janssen, BJ1
Hermans, JJ1
Peutz-Kootstra, C1
Witzke, O1
Smits, JF2
Struijker Boudier, HA1
Vellaichamy, E1
Zhao, D1
Somanna, N1
Pandey, KN1
Shi, YX1
Chen, Y1
Zhu, YZ1
Huang, GY1
Moore, PK1
Huang, SH1
Yao, T1
Zhu, YC1
Rugale, C1
Delbosc, S1
Mimran, A1
Jover, B1
Kobayashi, A1
Ishikawa, K4
Matsumoto, H1
Kimura, S1
Kamiyama, Y1
Maruyama, Y1
Menard, J1
Michel, JB1
Dussaule, JC1
Alhenc-Gelas, F1
Corvol, P1
Artese, D1
Albani, A1
Di Tomasso, E1
Hilliker, KS1
Roth, RA1
Bing, OH1
Conrad, CH1
Brooks, WW1
Tarazi, RC2
Greenberg, BH1
Rahimtoola, SH1
Bolte, HD1
Limas, CJ1
Spier, SS1
Beekman, RH1
Rocchini, AP1
Rosenthal, A1
Pegram, BL1
Ishise, S1
Frohlich, ED1
Numaguchi, K1
Egashira, K1
Takemoto, M1
Kadokami, T1
Shimokawa, H1
Sueishi, K1
Takeshita, A1
Golomb, E1
Abassi, ZA1
Cuda, G1
Stylianou, M1
Panchal, VR1
Trachewsky, D1
Keiser, HR1
Benetos, A1
Albaladejo, P1
Levy, BI1
Safar, ME1
Kohno, M2
Fukui, T1
Horio, T2
Yokokawa, K2
Yasunari, K2
Yoshiyama, M1
Kurihara, N2
Takeda, T2
Cohn, JN1
Johnson, GR1
Shabetai, R1
Loeb, H1
Tristani, F1
Rector, T1
Smith, R1
Fletcher, R1
Reddy, DS1
Singh, M1
Ganguly, NK1
Mitchell, GF1
Pfeffer, MA1
Finn, PV1
Pfeffer, JM1
Zolk, O1
Flesch, M1
Schnabel, P1
Teisman, AC1
Pinto, YM1
van Gilst, WH1
Paul, M1
Böhm, M1
Kai, T3
Kino, H1
Shimada, S2
Sugimura, K2
Kurooka, A2
Takenaka, T1
Fukamizu, A1
Murakami, K1
Anderson, NH1
Devlin, AM2
Graham, D1
Morton, JJ1
Hamilton, CA1
Reid, JL1
Schork, NJ1
Dominiczak, AF2
Brosnan, MJ1
Clark, JS1
Mullins, JJ1
Tea, BS1
Dam, TV1
Moreau, P1
Hamet, P1
deBlois, D1
Kim, L1
Lee, T1
Fu, J1
Ritchie, ME1
Kawano, H1
Cody, RJ1
Graf, K1
Goetze, S1
Kawano, Y1
Schnee, J1
Law, RE1
Hsueh, WA1
Mervaala, E1
Müller, DN2
Schmidt, F2
Park, JK2
Gross, V1
Bader, M1
Breu, V2
Ganten, D2
Haller, H2
Luft, FC2
Yamazaki, T1
Komuro, I1
Yazaki, Y1
Mervaala, EM1
Dechend, R1
Genersch, E1
Löffler, BM1
Schneider, W1
Tanabe, A1
Naruse, M1
Adachi, C1
Seki, T1
Yoshimoto, T1
Takagi, S1
Naruse, K1
Takano, K1
Papst, PJ1
Ueda, Y1
Sakata, Y1
Kuzuya, T1
Terada, N1
Nakaya, H1
Sasamura, H1
Hayashi, M1
Saruta, T1
Knowles, JW1
Esposito, G1
Mao, L1
Hagaman, JR1
Fox, JE1
Smithies, O1
Rockman, HA1
Maeda, N1
Paull, JR1
Widdop, RE1
Connor, G1
Wilburn, RL1
Bennett, CM1
Manegold, C1
Patzschke, U1
Markenson, JA1
Sherman, RL1
Yamada, T1
Kubota, T1
Endo, T1
Komatus, H1
Oba, M1
Nagata, H1
Izumiyama, T1
Lloyd, EA1
Ferrante, F1
Bronzetti, E1
Ciriaco, E1
Felici, L1
Amenta, F1
Yuan, B1
Leenen, FH6
Nagano, M1
Higaki, J1
Nakamura, F1
Higashimori, K1
Nagano, N1
Mikami, H1
Ogihara, T1
Cleutjens, JP1
van Krimpen, C1
Schoemaker, RG1
Daemen, MJ1
Clozel, JP1
Véniant, M1
Hess, P1
Sprecher, U1
Matsubara, H1
Yamamoto, J1
Hirata, Y1
Mori, Y1
Oikawa, S1
Inada, M1
Canby, CA2
Tomanek, RJ2
Murakawa, K1
Strauer, BE1
Tsoporis, J3
Yuan, BX1
Vial, JH1
Yong, AC1
Boyd, GW1
Nielsen, H1
Christensen, HR1
Christensen, KL1
Baandrup, U1
Jespersen, LT1
Anderson, PG2
Bishop, SP2
Digerness, SB2
Narayan, S1
Janicki, JS1
Shroff, SG1
Pick, R1
Weber, KT1
Bedotto, JB1
Gay, RG1
Graham, SD1
Morkin, E1
Goldman, S1
Fujii, S1
Kawaguchi, H1
Okamoto, H1
Saito, H1
Togashi, H1
Yasuda, H1
Rambausek, M1
Ritz, E1
Mall, G1
Mehls, O1
Katus, H1
Smith, DL1
Farkas, RM1
Reeves, RA1
Marquez-Julio, A1
Kiowski, W1
Burkart, F1
Lalich, JJ1
Paik, WC1
Poblete, PF1
Kyle, MC1
Pipberger, HV1
Freis, ED1
Weiss, L1
Khairallah, PA1
Bumpus, FM1
Kilcoyne, MM1
Thomson, GE1
Branche, G1
Williams, M1
Garnier, C1
Chiles, B1
Soland, T1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT00005122]0 participants Observational1958-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

4 reviews available for hydralazine and Cardiomegaly

ArticleYear
[Treatment of heart failure with vasodilators].
    Der Internist, 1980, Volume: 21, Issue:12

    Topics: Captopril; Cardiomegaly; Cardiotonic Agents; Coronary Disease; Heart Failure; Heart Function Tests;

1980
Role of the renin-angiotensin system in cardiac hypertrophy.
    The American journal of cardiology, 1999, Jun-17, Volume: 83, Issue:12A

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles;

1999
The use of vasodilator agents in the treatment of heart failure.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1979, Nov-10, Volume: 56, Issue:20

    Topics: Cardiac Output; Cardiomegaly; Catheterization; Chronic Disease; Coronary Vessels; Dose-Response Rela

1979
Cardiac remodeling in hypertension and following myocardial infarction: effects of arteriolar vasodilators.
    Basic research in cardiology, 1991, Volume: 86 Suppl 1

    Topics: Animals; Arterioles; Cardiomegaly; Extracellular Matrix; Humans; Hydralazine; Hypertension; Myocardi

1991

Trials

4 trials available for hydralazine and Cardiomegaly

ArticleYear
Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group.
    Circulation, 1993, Volume: 87, Issue:6 Suppl

    Topics: Arrhythmias, Cardiac; Cardiomegaly; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hyd

1993
Double-blind comparison of minoxidil and hydrallazine in severe hypertension.
    Clinical science and molecular medicine. Supplement, 1976, Volume: 3

    Topics: Adult; Aged; Cardiomegaly; Creatinine; Female; Humans; Hydralazine; Hypertension; Male; Middle Aged;

1976
Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans.
    The American journal of medicine, 1987, Volume: 82, Issue:5

    Topics: Adult; Cardiomegaly; Female; Humans; Hydralazine; Hypertension; Male; Middle Aged; Prazosin; Vasodil

1987
Effect of treatment on morbidity in hypertension. Veterans Administration Cooperative Study on Antihypertensive Agents. Effect on the electrocardiogram.
    Circulation, 1973, Volume: 48, Issue:3

    Topics: Antihypertensive Agents; Arrhythmias, Cardiac; Blood Pressure; Cardiomegaly; Clinical Trials as Topi

1973

Other Studies

82 other studies available for hydralazine and Cardiomegaly

ArticleYear
Reduced hemodynamic load aids low-dose resveratrol in reversing cardiovascular defects in hypertensive rats.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2013, Volume: 36, Issue:10

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Cardiovascular System; Disease Model

2013
High-salt intake induces cardiomyocyte hypertrophy in rats in response to local angiotensin II type 1 receptor activation.
    The Journal of nutrition, 2014, Volume: 144, Issue:10

    Topics: Acetylcysteine; Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Body

2014
Olmesartan Inhibits Cardiac Hypertrophy in Mice Overexpressing Renin Independently of Blood Pressure: Its Beneficial Effects on ACE2/Ang(1-7)/Mas Axis and NADPH Oxidase Expression.
    Journal of cardiovascular pharmacology, 2016, Volume: 67, Issue:6

    Topics: Animals; Blood Pressure; Cardiomegaly; Fibrosis; Gene Expression; Hydralazine; Imidazoles; Male; Mic

2016
Role of cardiac hypertrophy in reducing the sensitivity of cardiopulmonary reflex control of renal sympathetic nerve activity in spontaneously hypertensive rats.
    Clinical and experimental pharmacology & physiology, 2008, Volume: 35, Issue:9

    Topics: Animals; Antihypertensive Agents; Baroreflex; Body Weight; Cardiomegaly; Enalapril; Heart; Hemodynam

2008
Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure.
    Kidney international, 2009, Volume: 75, Issue:8

    Topics: Animals; Blood Pressure; Cardiomegaly; Cardiomyopathy, Hypertrophic; Carrier Proteins; Extracellular

2009
Angiotensin II receptor blocker candesartan cilexetil, but not hydralazine hydrochloride, protects against mouse cardiac enlargement resulting from undernutrition in utero.
    Reproductive sciences (Thousand Oaks, Calif.), 2009, Volume: 16, Issue:10

    Topics: Animals; Benzimidazoles; Biphenyl Compounds; Caloric Restriction; Cardiomegaly; Disease Models, Anim

2009
Vasodilator therapy with hydralazine induces angiotensin AT receptor-mediated cardiomyocyte growth in mice lacking guanylyl cyclase-A.
    British journal of pharmacology, 2010, Volume: 159, Issue:5

    Topics: Animals; Blood Pressure; Cardiomegaly; Fibrosis; Gene Expression; Hydralazine; Male; Mice; Mice, Inb

2010
HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats.
    Hypertension (Dallas, Tex. : 1979), 2010, Volume: 56, Issue:3

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Echocardiography; Histone Deacetylas

2010
Salt-induced cardiac hypertrophy and interstitial fibrosis are due to a blood pressure-independent mechanism in Wistar rats.
    The Journal of nutrition, 2010, Volume: 140, Issue:10

    Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agen

2010
Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin II type 1 receptor blocker olmesartan.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2010, Volume: 33, Issue:12

    Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Car

2010
Opening of the adenosine triphosphate-sensitive potassium channel attenuates cardiac remodeling induced by long-term inhibition of nitric oxide synthesis: role of 70-kDa S6 kinase and extracellular signal-regulated kinase.
    Journal of the American College of Cardiology, 2002, Sep-04, Volume: 40, Issue:5

    Topics: Adenosine Triphosphate; Animals; Blood Pressure; Body Weight; Cardiomegaly; Glyburide; Hydralazine;

2002
[Opening of ATP-sensitive potassium channel attenuates cardiac remodeling induced by chronic inhibition of nitric oxide synthesis].
    Journal of cardiology, 2003, Volume: 41, Issue:1

    Topics: Adenosine Triphosphate; Animals; Blood Pressure; Cardiomegaly; Chromans; Hydralazine; Mitogen-Activa

2003
Hydralazine as antihypertensive therapy in obesity-related hypertension.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2004, Volume: 28, Issue:3

    Topics: Animals; Antihypertensive Agents; Biometry; Blood Pressure; Cardiomegaly; Female; Heart Rate; Hormon

2004
Inhibition of NF-kappaB induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats.
    American journal of physiology. Heart and circulatory physiology, 2005, Volume: 289, Issue:1

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Cardiomegaly; Disease

2005
Angiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension induced by chronic nitric oxide inhibition.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2006, Volume: 29, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl

2006
p38 MAP kinase activity is correlated with angiotensin II type 1 receptor blocker-induced left ventricular reverse remodeling in spontaneously hypertensive heart failure rats.
    Journal of cardiac failure, 2006, Volume: 12, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiomegaly; Female; Heart Failure; Hydralazine;

2006
Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis.
    Journal of hypertension, 2006, Volume: 24, Issue:10

    Topics: Amlodipine; Animals; Azetidinecarboxylic Acid; Cardiomegaly; Dihydropyridines; Endomyocardial Fibros

2006
Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age.
    Journal of hypertension, 2007, Volume: 25, Issue:1

    Topics: Age Factors; Aging; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; C

2007
Genetic disruption of guanylyl cyclase/natriuretic peptide receptor-A upregulates ACE and AT1 receptor gene expression and signaling: role in cardiac hypertrophy.
    Physiological genomics, 2007, Oct-22, Volume: 31, Issue:2

    Topics: Angiotensin II; Animals; Captopril; Cardiomegaly; Cyclic GMP; Fibrosis; Gene Expression Regulation;

2007
Chronic sodium hydrosulfide treatment decreases medial thickening of intramyocardial coronary arterioles, interstitial fibrosis, and ROS production in spontaneously hypertensive rats.
    American journal of physiology. Heart and circulatory physiology, 2007, Volume: 293, Issue:4

    Topics: Animals; Antihypertensive Agents; Blood Chemical Analysis; Blood Pressure; Cardiomegaly; Cardiotonic

2007
Simvastatin reverses target organ damage and oxidative stress in Angiotensin II hypertension: comparison with apocynin, tempol, and hydralazine.
    Journal of cardiovascular pharmacology, 2007, Volume: 50, Issue:3

    Topics: Acetophenones; Albuminuria; Angiotensin II; Animals; Antihypertensive Agents; Antioxidants; Cardiome

2007
Synergetic antioxidant and vasodilatory action of carbon monoxide in angiotensin II - induced cardiac hypertrophy.
    Hypertension (Dallas, Tex. : 1979), 2007, Volume: 50, Issue:6

    Topics: Angiotensin II; Animals; Antioxidants; Aorta; Blood Pressure; Carbon Monoxide; Carboxyhemoglobin; Ca

2007
Potentials and limitations of angiotensin converting enzyme inhibition in the treatment of hypertension.
    British journal of clinical pharmacology, 1984, Volume: 18 Suppl 2

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Cardiomegaly; Clonidine;

1984
[Vasodilator drugs in the therapy of chronic congestive heart failure. Clinico-case contribution].
    Minerva medica, 1983, Mar-31, Volume: 74, Issue:13

    Topics: Blood Pressure; Cardiomegaly; Chronic Disease; Drug Evaluation; Heart; Heart Failure; Humans; Hydral

1983
Alteration of monocrotaline pyrrole-induced cardiopulmonary effects in rats by hydrallazine, dexamethasone or sulphinpyrazone.
    British journal of pharmacology, 1984, Volume: 82, Issue:2

    Topics: Animals; Body Weight; Cardiomegaly; Dexamethasone; Heart Diseases; Hydralazine; L-Lactate Dehydrogen

1984
Myocardial function structure and collagen in the spontaneously hypertensive rat: progression from compensated hypertrophy to haemodynamic impairment.
    European heart journal, 1984, Volume: 5 Suppl F

    Topics: Animals; Body Weight; Cardiomegaly; Collagen; Guanethidine; Heart Failure; Hydralazine; Hypertension

1984
Regression of myocardial hypertrophy and influence of adrenergic system.
    The American journal of physiology, 1983, Volume: 244, Issue:1

    Topics: Animals; Blood Pressure; Cardiomegaly; Catecholamines; Dose-Response Relationship, Drug; Hydralazine

1983
Long-term vasodilator therapy in aortic insufficiency. Evidence for regression of left ventricular dilatation and hypertrophy and improvement in systolic pump function.
    Annals of internal medicine, 1980, Volume: 93, Issue:3

    Topics: Aortic Valve Insufficiency; Cardiac Catheterization; Cardiomegaly; Female; Humans; Hydralazine; Midd

1980
Effect of antihypertensive therapy on calcium transport by cardiac sarcoplasmic reticulum of SHRs.
    Cardiovascular research, 1980, Volume: 14, Issue:12

    Topics: Adenosine Triphosphatases; Animals; Biological Transport; Calcium; Cardiomegaly; Hydralazine; Hypert

1980
Hemodynamic effects of hydralazine in infants with a large ventricular septal defect.
    Circulation, 1982, Volume: 65, Issue:3

    Topics: Blood Pressure; Cardiomegaly; Female; Heart Failure; Heart Septal Defects, Ventricular; Hemodynamics

1982
Effect of methyldopa, clonidine, and hydralazine on cardiac mass and haemodynamics in Wistar Kyoto and spontaneously hypertensive rats.
    Cardiovascular research, 1982, Volume: 16, Issue:1

    Topics: Animals; Cardiomegaly; Clonidine; Heart; Hemodynamics; Hydralazine; Hypertension; Methyldopa; Organ

1982
Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats.
    Hypertension (Dallas, Tex. : 1979), 1995, Volume: 26, Issue:6 Pt 1

    Topics: Animals; Arginine; Blood Pressure; Cardiomegaly; Coronary Circulation; Coronary Vessels; Data Interp

1995
Angiotensin II maintains, but does not mediate, isoproterenol-induced cardiac hypertrophy in rats.
    The American journal of physiology, 1994, Volume: 267, Issue:4 Pt 2

    Topics: Actins; Angiotensin II; Animals; Base Sequence; Biphenyl Compounds; Blood Pressure; Captopril; Cardi

1994
Acute and long-term effects of angiotensin converting enzyme inhibition on larger arteries and cardiac hypertrophy: mechanical and structural parameters.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1994, Volume: 12, Issue:4

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arteries; Blood Pressure; Cardiomegaly; Complianc

1994
Cardiac hypertrophy and brain natriuretic peptide in experimental hypertension.
    The American journal of physiology, 1994, Volume: 266, Issue:2 Pt 2

    Topics: Animals; Atrial Natriuretic Factor; Biphenyl Compounds; Blood Pressure; Blood Urea Nitrogen; Cardiom

1994
Effects of long-term hydralazine treatment on myocardial structure and expression of myosin isogenes in cardiac pressure overload in rats.
    Methods and findings in experimental and clinical pharmacology, 1996, Volume: 18, Issue:4

    Topics: Analysis of Variance; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Disease Models

1996
Equipotent antihypertensive agents variously affect pulsatile hemodynamics and regression of cardiac hypertrophy in spontaneously hypertensive rats.
    Circulation, 1996, Dec-01, Volume: 94, Issue:11

    Topics: Animals; Antihypertensive Agents; Captopril; Cardiomegaly; Hemodynamics; Hydralazine; Hypertension;

1996
Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and beta-adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats.
    British journal of pharmacology, 1998, Volume: 123, Issue:3

    Topics: Adenylyl Cyclases; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anima

1998
Role of the renin-angiotensin system in cardiac hypertrophy and renal glomerular sclerosis in transgenic hypertensive mice carrying both human renin and angiotensinogen genes.
    Hypertension research : official journal of the Japanese Society of Hypertension, 1998, Volume: 21, Issue:1

    Topics: Albuminuria; Angiotensinogen; Animals; Blood Pressure; Cardiomegaly; Drinking; Fibronectins; Gene Ex

1998
Tissue-localized angiotensin II enhances cardiac and renal disorders in Tsukuba hypertensive mice.
    Journal of hypertension, 1998, Volume: 16, Issue:12 Pt 2

    Topics: Angiotensin II; Angiotensinogen; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Cat

1998
Telemetry for cardiovascular monitoring in a pharmacological study: new approaches to data analysis.
    Hypertension (Dallas, Tex. : 1979), 1999, Volume: 33, Issue:1 Pt 2

    Topics: Animals; Antihypertensive Agents; Aorta; Blood Pressure; Cardiomegaly; Cell Nucleus; Diastole; DNA;

1999
Renin-angiotensin system stimulates cardiac and renal disorders in Tsukuba hypertensive mice.
    Clinical and experimental pharmacology & physiology, 1999, Volume: 26, Issue:3

    Topics: Angiotensin II; Angiotensinogen; Animals; Blood Pressure; Cardiomegaly; Humans; Hydralazine; Hyperte

1999
Different effects of antihypertensive agents on cardiac and vascular hypertrophy in the transgenic rat line TGR(mRen2)27.
    American journal of hypertension, 1999, Volume: 12, Issue:7

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive A

1999
Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats. Temporal regulation and spatial heterogeneity.
    Hypertension (Dallas, Tex. : 1979), 1999, Volume: 34, Issue:2

    Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit

1999
Characterization of MAP kinase and PKC isoform and effect of ACE inhibition in hypertrophy in vivo.
    The American journal of physiology, 1999, Volume: 277, Issue:5

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Cardiomegaly; Enzyme Act

1999
Angiotensin II enhances integrin and alpha-actinin expression in adult rat cardiac fibroblasts.
    Hypertension (Dallas, Tex. : 1979), 2000, Volume: 35, Issue:1 Pt 2

    Topics: Actinin; Age Factors; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antigens, CD; Antih

2000
Blood pressure-independent effects in rats with human renin and angiotensinogen genes.
    Hypertension (Dallas, Tex. : 1979), 2000, Volume: 35, Issue:2

    Topics: Albuminuria; Angiotensin II; Angiotensinogen; Animals; Animals, Genetically Modified; Antihypertensi

2000
Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage.
    Hypertension (Dallas, Tex. : 1979), 2000, Volume: 36, Issue:2

    Topics: Albuminuria; Angiotensin II; Angiotensinogen; Animals; Animals, Genetically Modified; Antihypertensi

2000
Hydralazine decreases blood pressure and endothelin-1 mRNA expression in tissues but not cardiac weight in SHR-SP/Izm rats.
    Journal of cardiovascular pharmacology, 2000, Volume: 36, Issue:5 Suppl 1

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Cardiomegaly; Endothelin-1; Hydralazi

2000
Inhibition of nitric oxide synthesis induces coronary vascular remodeling and cardiac hypertrophy associated with the activation of p70 S6 kinase in rats.
    Cardiovascular drugs and therapy, 2000, Volume: 14, Issue:5

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cardiomegaly; Coronary Vessels; D

2000
Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis.
    Journal of the American Society of Nephrology : JASN, 2001, Volume: 12, Issue:4

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angioten

2001
Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice.
    The Journal of clinical investigation, 2001, Volume: 107, Issue:8

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Enalapril; Furosemide; Guanylate Cyc

2001
Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats.
    Journal of hypertension, 2001, Volume: 19, Issue:8

    Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib

2001
[Regression of left ventricular hypertophy in the ECG during antihypertensive treatment: preliminary observations (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1979, Jun-08, Volume: 104, Issue:23

    Topics: Adult; Aged; Cardiomegaly; Chlorthalidone; Electrocardiography; Female; Humans; Hydralazine; Hyperte

1979
Renal involvement in progressive systemic sclerosis: prolonged survival with aggressive antihypertensive management.
    Arthritis and rheumatism, 1979, Volume: 22, Issue:10

    Topics: Adult; Antihypertensive Agents; Cardiomegaly; Digoxin; Drug Therapy, Combination; Female; Furosemide

1979
Effects of antihypertensive treatment on left ventricular hypertrophy in patients with essential hypertension.
    Journal of the American Geriatrics Society, 1979, Volume: 27, Issue:11

    Topics: Adult; Aged; Animals; Antihypertensive Agents; Cardiomegaly; Electrocardiography; Female; Heart Vent

1979
Effect of nicardipine treatment upon cardiac hypertrophy in spontaneously hypertensive rats: a morphometric and ultrastructural study.
    Journal of hypertension, 1992, Volume: 10, Issue:6

    Topics: Animals; Cardiomegaly; Drug Evaluation, Preclinical; Hydralazine; Hypertension; Male; Microscopy, El

1992
Chronic arterial vasodilation, central hemodynamics, and cardiac hypertrophy in spontaneously hypertensive rats.
    Journal of cardiovascular pharmacology, 1992, Volume: 19, Issue:6

    Topics: Animals; Arteries; Blood Pressure; Body Weight; Cardiac Output; Cardiomegaly; Drinking; Heart Rate;

1992
Role of cardiac angiotensin II in isoproterenol-induced left ventricular hypertrophy.
    Hypertension (Dallas, Tex. : 1979), 1992, Volume: 19, Issue:6 Pt 2

    Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Card

1992
Effects of two angiotensin converting enzyme inhibitors and hydralazine on coronary circulation in hypertensive rats.
    Hypertension (Dallas, Tex. : 1979), 1991, Volume: 18, Issue:4 Suppl

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Cardiomegaly; Cilazapril; Coronary Cir

1991
Changes of atrial natriuretic peptide and its messenger RNA with development and regression of cardiac hypertrophy in renovascular hypertensive rats.
    Circulation research, 1990, Volume: 66, Issue:1

    Topics: Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blotting, Northern; Cardiomegaly; Enala

1990
Regression of ventricular hypertrophy abolishes cardiocyte vulnerability to acute hypoxia.
    The Anatomical record, 1990, Volume: 226, Issue:2

    Topics: Animals; Blood Gas Analysis; Blood Pressure; Body Weight; Captopril; Cardiomegaly; Heart; Hemodynami

1990
Effect on atrial natriuretic peptides of chronic treatment with alpha-methyldopa and hydralazine in spontaneously hypertensive rats.
    American journal of hypertension, 1990, Volume: 3, Issue:2

    Topics: Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Heart Atria; Heart Ventricles; Hyd

1990
Significance of coronary circulation in hypertensive heart disease for development and prevention of heart failure.
    The American journal of cardiology, 1990, Apr-03, Volume: 65, Issue:14

    Topics: Adult; Animals; Cardiac Output, Low; Cardiomegaly; Coronary Circulation; Coronary Disease; Coronary

1990
Left ventricular hypertrophy in hypertensive patients.
    The American journal of medicine, 1989, Jan-23, Volume: 86, Issue:1B

    Topics: Cardiomegaly; Drug Therapy, Combination; Humans; Hydralazine; Hypertension; Prazosin

1989
Arterial vasodilators, cardiac volume load, and cardiac hypertrophy in normotensive rats.
    The American journal of physiology, 1989, Volume: 256, Issue:3 Pt 2

    Topics: Animals; Arteries; Blood Pressure; Blood Volume; Cardiomegaly; Heart Rate; Heart Ventricles; Hydrala

1989
Structural change in the rat hindlimb during deoxycorticosterone acetate hypertension; its reversibility and prevention.
    Journal of hypertension, 1989, Volume: 7, Issue:2

    Topics: Animals; Arterioles; Cardiomegaly; Desoxycorticosterone; Hindlimb; Hydralazine; Hypertension; Male;

1989
Antitrophic properties of antihypertensive drugs may depend solely on their blood pressure-lowering capability. A comparative study of isradipine, hydralazine, and metoprolol.
    The American journal of medicine, 1989, Apr-17, Volume: 86, Issue:4A

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiomegaly; Coronary V

1989
Vascular remodeling and improvement of coronary reserve after hydralazine treatment in spontaneously hypertensive rats.
    Circulation research, 1989, Volume: 64, Issue:6

    Topics: Animals; Cardiac Volume; Cardiomegaly; Coronary Circulation; Coronary Vessels; Hydralazine; Hyperten

1989
Role of lowering arterial pressure on maximal coronary flow with and without regression of cardiac hypertrophy.
    The American journal of physiology, 1989, Volume: 257, Issue:4 Pt 2

    Topics: Animals; Blood Pressure; Body Weight; Captopril; Cardiomegaly; Coronary Circulation; Heart; Hydralaz

1989
Myocardial collagen and mechanics after preventing hypertrophy in hypertensive rats.
    American journal of hypertension, 1989, Volume: 2, Issue:9

    Topics: Animals; Blood Pressure; Cardiomegaly; Collagen; Hemodynamics; Hydralazine; Hypertension; Myocardium

1989
Cardiac hypertrophy induced by thyroid hormone is independent of loading conditions and beta adrenoceptor blockade.
    The Journal of pharmacology and experimental therapeutics, 1989, Volume: 248, Issue:2

    Topics: Animals; Captopril; Cardiomegaly; Heart; Hydralazine; Isoenzymes; Male; Myosins; Propranolol; Rats;

1989
Fatty acid binding protein of cardiac muscle in spontaneously hypertensive rats: effect of hypertrophy and its regression.
    Journal of molecular and cellular cardiology, 1988, Volume: 20, Issue:9

    Topics: Animals; Blood Pressure; Cardiomegaly; Carrier Proteins; Enalapril; Fatty Acid-Binding Protein 7; Fa

1988
Effects of arterial vasodilators on cardiac hypertrophy and sympathetic activity in rats.
    Hypertension (Dallas, Tex. : 1979), 1988, Volume: 11, Issue:4

    Topics: Animals; Blood Pressure; Blood Volume; Body Weight; Cardiomegaly; Epinephrine; Heart; Heart Rate; He

1988
Myocardial hypertrophy in rats with renal insufficiency.
    Kidney international, 1985, Volume: 28, Issue:5

    Topics: Adenosine Triphosphatases; Animals; Blood Pressure; Blood Transfusion; Calcium; Cardiomegaly; Hydral

1985
Effects of hydralazine on blood pressure, pressor mechanisms, and cardiac hypertrophy in two-kidney, one-clip hypertensive rats.
    Canadian journal of physiology and pharmacology, 1986, Volume: 64, Issue:12

    Topics: Animals; Blood Pressure; Blood Volume; Cardiomegaly; Drug Tolerance; Hydralazine; Hypertension, Reno

1986
Effects of vasodilators on the coronary circulation in congestive heart failure.
    The American journal of cardiology, 1988, Sep-09, Volume: 62, Issue:8

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Cardiomegaly; Cilazapri

1988
Coronary vascular function and morphology in hydralazine treated DOCA salt rats.
    Journal of molecular and cellular cardiology, 1988, Volume: 20, Issue:10

    Topics: Animals; Cardiomegaly; Coronary Vessels; Desoxycorticosterone; Hydralazine; Hypertension; Rats; Rats

1988
Influence of hydralazine consumption on allylamine induced myocardial fibrosis and hypertrophy in rats.
    Experimental and molecular pathology, 1974, Volume: 21, Issue:1

    Topics: Allyl Compounds; Amines; Animals; Aorta, Thoracic; Cardiomegaly; Coronary Vessels; Diet; Endomyocard

1974
Aspects of the relation between functional and structural cardiovascular factors in primary hypertension. Experimental studies in spontaneously hypertensive rats.
    Acta physiologica Scandinavica. Supplementum, 1974, Volume: 409

    Topics: Animals; Aorta; Blood Pressure; Capillary Resistance; Cardiac Output; Cardiomegaly; Coronary Circula

1974
Cardiac hypertrophy in spontaneously hypertensive rats.
    Circulation research, 1974, Volume: 35, Issue:5

    Topics: Age Factors; Angiotensin II; Animals; Cardiomegaly; DNA; Heart Ventricles; Hydralazine; Hypertension

1974
Characteristics of hypertension in the black population.
    Circulation, 1974, Volume: 50, Issue:5

    Topics: Adult; Angiotensin II; Animals; Black or African American; Cardiomegaly; Cerebrovascular Disorders;

1974
chemdatabank.com